5 Key Takeaways

• 1

  EYP-1901, a potent tyrosine kinase inhibitor, demonstrated sustained efficacy in treating diabetic macular edema (DME) in the VERONA phase 2 trial.

• 2

  The trial showed that 73% of high-dose EYP-1901 patients were supplement-free at 24 weeks, outperforming the 50% in the aflibercept group.

• 3

  EYP-1901 treatment resulted in significant visual acuity improvements as early as week 4, with better outcomes in the high-dose group.

• 4

  Safety data indicated no serious adverse events related to EYP-1901, confirming its favorable safety profile in the DME study.

• 5

  The VERONA study's success positions EYP-1901 for potential phase 3 trials, indicating promising future for DME treatment.